Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI)

Fibrinolysis

Volumn 10, Issue SUPPL. 2, 1996, Pages 13-16

  Iacoviello, L ^a,d   Di Castelnuovo, A ^a   De Knijff, P ^b,c   D'Orazio, A ^a   Amore, C ^a   Kluft, C ^b   Donati, M B ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

CONFERENCE PAPER; FIBRINOLYSIS; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029855647     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80036-1     Document Type: Conference Paper

References (12)

1. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
2. ECAT Angina Pectoris Study Group: ECAT angina pectoris study: baseline association of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
3. Hamsten A, Wiman B, DeFaire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
4. Ridker P M, Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
5. Jansson J H, Nilsson T K, Olofsson B O: Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-161.
6. Nilsson T K, Olofsson B O, Jansson J H: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with angiographically verified coronary heart disease: a 7 years follow-up. Circulation 1992; 86:598.
7. Ten Cate L P, Boman H, Daiger S P, Motulsky A G: Familial aggregation of coronary heart disease and its relation to known genetic risk factors. Am J Cardiol 1982; 50: 945-953.
8. Roncaglioni M C, Santoro L, D'Avanzo B, Negri E, Nobili A, Ledda A, Pietropaolo F, Franzosi M G, La Vecchia C, Feruglio G A, Maseri A: Role of family history in patients with myocardial infarction: an Italian case-control study. Circulation 1992; 85: 2065-2072.
9. Humphries S. The genetic contribution to the risk of thrombosis and cardiovascular disease. Trends Cardiovasc Med 1994; 4: 8-17.
10. Francis R, McCloyn V. Patch J, Kovacs B, Grim C: Genetic influences on fibrinolysis: studies in twins. Blood 1990; 76 (Suppl 2):2017.
11. Ludwig M, Wohn K-D, Schleuning W., Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 1992; 88: 388-92.
12. Van den Eijnden-Schrauwen Y, Lakenberg N, Emeis J J, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene does not affect basal endothelial t-PA synthesis. Thromb Haemost 1995; 74: 1202.